Bristol-Myers Squibb (BMY) Earnings Date & Reports

Key Takeaways

• Bristol-Myers Squibb (BMY) is scheduled to report second-quarter 2026 results on Thursday, July 30, before the market opens, with a conference call at 8:15 a.m. ET.
• Wall Street consensus projects adjusted earnings per share (EPS) of approximately $1.61, which would represent a roughly 10% increase from the $1.46 reported in the prior-year quarter.
• Revenue is expected to land near $11.70 billion, reflecting an anticipated year-over-year decline as generic erosion in the Legacy Portfolio continues to weigh on top-line results.
• The company has exceeded EPS estimates in each of its last four consecutive quarters, most recently delivering $1.58 against a $1.42 consensus in Q1 2026.
• Investor attention will center on the performance of key Growth Portfolio drugs — including Camzyos, Breyanzi, Reblozyl, and Cobenfy — as management works to offset declining sales from legacy products facing generic competition.
• Full-year 2026 guidance, which management reaffirmed in April and indicated is trending toward the upper end, calls for total revenue of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35.

Earnings Context and Why It Matters

Bristol-Myers Squibb's second-quarter report arrives at a pivotal juncture for the $117-billion pharmaceutical giant. The company is navigating a well-documented transition: its Legacy Portfolio — anchored by the blood thinner Eliquis and the multiple myeloma treatment Revlimid — continues to face intensifying generic erosion, while its Growth Portfolio of newer therapies must carry an increasingly larger share of the revenue base. With blockbuster patent expirations for Eliquis and Opdivo on the horizon in 2028, every quarterly update serves as a progress report on whether the pipeline is scaling fast enough. Investors will scrutinize this Q2 print for evidence that newer drugs such as Camzyos, Breyanzi, Reblozyl, and the recently launched schizophrenia treatment Cobenfy can sustain the momentum that powered a 12% year-over-year increase in Growth Portfolio revenue during the first quarter.

Earnings Expectations

Analyst consensus ahead of the July 30 release points to adjusted EPS of $1.61, with estimates ranging from $1.48 to $1.71, according to data compiled from major financial platforms. Revenue expectations center on approximately $11.70 billion, which would mark a decline from the $12.23 billion reported in Q2 2025, largely reflecting the anticipated continued erosion of Revlimid and other mature brands. For context, in Q1 2026, Bristol-Myers Squibb posted revenue of $11.49 billion (up 3% year-over-year on a reported basis) and non-GAAP EPS of $1.58, handily beating consensus on both the top and bottom lines. The Growth Portfolio generated $6.2 billion in Q1, a 12% increase fueled by standout performances from Camzyos (up 97% to $314 million), Breyanzi (up 56% to $411 million), and Reblozyl (up 16% to $555 million). Cobenfy, the company's novel schizophrenia therapy, contributed $56 million in its early launch phase. On the Legacy side, Eliquis remained a cash-flow powerhouse at $4.14 billion (up 16%), while Revlimid plunged 63% to $349 million as generic lenalidomide became fully unrestricted in the U.S. market starting in early 2026.

Management reaffirmed full-year 2026 guidance during the Q1 call, projecting total revenue of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35, with both metrics described as tracking toward the upper end of the ranges. Gross margin is expected at approximately 69%–70%, reflecting the product-mix shift as higher-margin legacy products decline. Investors will listen closely on the Q2 call for any adjustments to this outlook.

AI Screener

For investors looking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener provides an AI-powered stock and ETF discovery platform that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable parameters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. Whether you are searching for breakout candidates, trending stocks, or sector-specific trade ideas, the screener streamlines the discovery process and surfaces opportunities more efficiently than manual screening. Explore the AI Screener today to see how data-driven filtering can support your market research.

Market Reaction and Investor Sentiment

Heading into the Q2 report, Bristol-Myers Squibb shares have traded in a relatively contained range, reflecting a cautious but not bearish investor posture. The stock has gained approximately 6% year-to-date, supported by a dividend yield above 4% and the steady execution narrative around the Growth Portfolio. However, sentiment remains tempered by structural concerns: the 2028 patent cliff for Eliquis and Opdivo looms large, and some analysts project EPS to decline in fiscal 2027 as exclusivity losses begin to bite. The Q1 earnings beat in April was met with a muted market response — shares dipped slightly despite the upside surprise — suggesting that investors are weighing near-term execution against longer-duration risks. For Q2, the reaction will likely hinge on two factors: whether the Growth Portfolio sustains its double-digit expansion rate and whether management signals any change to the full-year outlook. A reaffirmed or raised guidance paired with strong pipeline metrics could provide a catalyst, while any softening in key growth products like Camzyos or Breyanzi would raise questions about the portfolio transition timeline.

Forward Outlook and Key Factors to Monitor

Looking beyond the second quarter, several dynamics will shape the Bristol-Myers Squibb investment narrative through the remainder of 2026 and into 2027.

The first priority is sustained Growth Portfolio acceleration. Camzyos, the company's cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (a condition where heart muscle becomes abnormally thick), nearly doubled sales in Q1 and represents one of the most closely watched commercial launches. Breyanzi, a CAR-T cell therapy (a type of cancer treatment that uses a patient's own reprogrammed immune cells) for certain blood cancers, is scaling rapidly across approved indications in both U.S. and international markets. Continued double-digit expansion from these assets is essential to offset the steepening decline of Revlimid and other legacy drugs.

Pipeline catalysts also demand attention. Bristol-Myers Squibb has indicated that pivotal late-stage readouts for Milvexian — an investigational oral Factor XIa inhibitor for stroke prevention in atrial fibrillation — are expected in late 2026. Positive data would meaningfully alter the post-patent-cliff growth trajectory. Additionally, the company is advancing clinical programs in neuroscience, including Cobenfy in Alzheimer's-related psychosis, with data readouts anticipated in the 2026–2027 window.

Cost discipline and margin management remain under the spotlight. The company's strategic productivity initiative targets $2 billion in cumulative savings by 2027, and management has cited artificial intelligence tools aimed at reducing research and development (R&D) cycle times by 30%. With gross margins compressing due to product mix, investors will monitor whether operating expense control can partially offset the profitability headwinds from legacy erosion.

Finally, capital allocation decisions — including the $0.63 quarterly dividend and the remaining $5 billion share repurchase authorization — signal management's confidence in cash generation. However, the sustainability of these shareholder returns will be tested as Eliquis and Opdivo approach their 2028 loss of exclusivity dates. For now, the second-quarter report offers the next checkpoint on whether the Growth Portfolio is shouldering enough of the revenue burden to keep the transition on track.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations